…
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -10.02M | -8.27M | -14.28M | -13.03M | -8.62M |
| Minority interest | 0.08M | 0.00M | -0.01M | -0.00M | -0.01M |
| Net income | -9.95M | -8.38M | -16.03M | -12.76M | -8.63M |
| Selling general administrative | 12.75M | 15.10M | 12.61M | 10.14M | 10.28M |
| Gross profit | 5.53M | 5.05M | 4.93M | 1.21M | 4.51M |
| Reconciled depreciation | 1.36M | 1.29M | 0.84M | 0.29M | 0.39M |
| Ebit | -11.81M | -13.97M | -12.29M | -12.53M | -9.12M |
| Ebitda | -10.45M | -21.38M | -9.69M | -12.63M | -7.47M |
| Depreciation and amortization | 1.36M | -7.41M | 2.60M | -0.09M | 1.65M |
| Non operating income net other | - | - | - | -0.38M | -1.30M |
| Operating income | -10.95M | -13.97M | -12.29M | -12.53M | -9.12M |
| Other operating expenses | 24.32M | 32.14M | 21.32M | 14.47M | 14.51M |
| Interest expense | - | -13.22M | 1.99M | 0.12M | 0.74M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Interest income | 0.08M | 0.01M | - | - | 1.81M |
| Net interest income | 0.08M | 0.01M | 0.01M | -0.12M | -0.16M |
| Income tax expense | -0.08M | 0.11M | 1.75M | -0.26M | 0.01M |
| Total revenue | 13.37M | 18.17M | 9.03M | 1.93M | 5.39M |
| Total operating expenses | 16.49M | 19.02M | 17.22M | 13.75M | 13.64M |
| Cost of revenue | 7.83M | 13.12M | 4.10M | 0.72M | 0.88M |
| Total other income expense net | 0.86M | 5.70M | -1.99M | -0.49M | 0.51M |
| Net income from continuing ops | -10.02M | -8.27M | -14.28M | -13.03M | -8.63M |
| Net income applicable to common shares | - | -8.38M | -14.29M | -13.03M | -8.93M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 13.65M | 22.27M | 14.42M | 11.34M | 3.56M |
| Intangible assets | 2.70M | - | - | 0.61M | 0.73M |
| Other current assets | 0.39M | 1.06M | 0.57M | 0.60M | 0.60M |
| Total liab | 8.78M | 9.36M | 3.30M | 5.63M | 4.41M |
| Total stockholder equity | 4.95M | 12.91M | 11.11M | 5.72M | -0.84M |
| Deferred long term liab | - | - | - | - | 0.11M |
| Other current liab | 1.20M | 1.88M | 0.98M | 0.68M | 0.46M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -302.45M | -292.50M | -284.12M | -269.84M | -256.81M |
| Other liab | - | 5.17M | 0.03M | 0.85M | 0.62M |
| Good will | - | - | - | 0.29M | 0.29M |
| Other assets | - | 0.10M | 0.10M | 0.10M | 0.17M |
| Cash | 7.15M | 15.22M | 6.55M | 7.79M | 0.56M |
| Total current liabilities | 2.85M | 4.19M | 3.27M | 4.27M | 2.25M |
| Current deferred revenue | 0.08M | 0.56M | 0.28M | 0.51M | 0.63M |
| Net debt | -5.91M | -15.22M | -6.55M | -5.44M | 0.99M |
| Short term debt | 0.50M | - | - | 1.83M | - |
| Short long term debt | - | - | - | 1.83M | - |
| Short long term debt total | 1.24M | - | - | 2.35M | 1.55M |
| Other stockholder equity | 307.38M | 305.40M | 295.23M | 275.55M | 255.96M |
| Property plant equipment | - | 2.22M | 3.02M | 1.28M | 0.23M |
| Total current assets | 8.13M | 19.94M | 11.30M | 9.08M | 2.15M |
| Net tangible assets | - | 12.91M | 11.11M | 4.83M | -1.86M |
| Net receivables | 0.26M | 3.07M | 2.80M | 0.19M | 0.84M |
| Long term debt | - | - | - | 0.52M | 1.44M |
| Inventory | 0.33M | 0.60M | 1.37M | 0.50M | 0.14M |
| Accounts payable | 1.07M | 1.74M | 2.01M | 1.25M | 1.15M |
| Noncontrolling interest in consolidated entity | - | - | - | -0.01M | -0.01M |
| Accumulated other comprehensive income | - | - | - | -2.45M | -2.29M |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Retained earnings total equity | - | - | - | -269.84M | -256.81M |
| Non currrent assets other | 0.75M | 0.10M | 0.10M | 0.10M | 0.17M |
| Deferred long term asset charges | - | - | - | - | 0.11M |
| Non current assets total | 5.53M | 2.32M | 3.12M | 2.26M | 1.42M |
| Capital lease obligations | 1.24M | - | - | - | - |
| Long term debt total | - | - | - | 0.52M | 1.44M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -1.10M | -0.49M | -2.55M | -1.06M | -0.07M |
| Change to liabilities | - | 1.21M | -0.14M | 0.43M | 0.67M |
| Total cashflows from investing activities | - | -0.49M | -2.55M | -1.06M | -0.07M |
| Net borrowings | - | - | -1.67M | 0.85M | 1.99M |
| Total cash from financing activities | 0.95M | 18.13M | 14.70M | 19.43M | 5.83M |
| Change to operating activities | - | -0.49M | 0.03M | -0.03M | 0.02M |
| Net income | -10.02M | -8.27M | -14.28M | -13.03M | -8.63M |
| Change in cash | -7.31M | 8.66M | -1.23M | 7.23M | -1.10M |
| Begin period cash flow | 15.22M | 6.55M | 7.79M | 0.56M | 1.66M |
| End period cash flow | 7.90M | 15.22M | 6.55M | 7.79M | 0.56M |
| Total cash from operating activities | -6.22M | -8.98M | -13.39M | -11.14M | -6.86M |
| Issuance of capital stock | 0.00M | 14.43M | 13.76M | 10.64M | 2.87M |
| Depreciation | 1.36M | 1.29M | 0.84M | 0.29M | 0.39M |
| Dividends paid | - | -0.11M | - | 0.00M | - |
| Change to inventory | 0.27M | 0.77M | -0.87M | -0.35M | 0.08M |
| Change to account receivables | 3.05M | -0.53M | -2.64M | 0.60M | 0.64M |
| Sale purchase of stock | 0.95M | - | - | 18.70M | 3.85M |
| Other cashflows from financing activities | -0.95M | 3.81M | 2.61M | 8.90M | 2.96M |
| Change to netincome | - | -2.95M | 3.67M | 1.05M | 2.65M |
| Capital expenditures | 0.08M | 0.49M | 2.55M | 1.06M | 0.07M |
| Change receivables | - | - | - | 0.60M | 0.64M |
| Cash flows other operating | - | - | - | -0.15M | -2.68M |
| Cash and cash equivalents changes | - | - | - | 7.23M | -1.10M |
| Change in working capital | 2.45M | 0.95M | -3.62M | 0.53M | 0.68M |
| Stock based compensation | 1.03M | 2.52M | 1.67M | 1.00M | 1.13M |
| Other non cash items | -1.72M | -5.47M | 1.99M | 0.03M | -1.70M |
| Free cash flow | -6.30M | -9.47M | -15.94M | -12.21M | -6.93M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
-17.51 2.54% |
671.24 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.25 0.11% |
220.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.77 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.92 3.87% |
22.85 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
50 Health Sciences Drive, Stony Brook, NY, United States, 11790
631 240 8800
52
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Hayward Ph.D., Sc.D. | Chairman, Pres & CEO | 1954 |
| Ms. Beth M. Jantzen CPA, CPA | Chief Financial Officer | 1976 |
| Ms. Judith Murrah | COO & Sec. | 1958 |
| Mr. Sanjay M. Hurry | Exec. Director of Investor Relations & Corp. Communications | NA |
| Mr. Clay Shorrock Esq., J.D. | Chief Legal Officer & Exec. Director of Bus. Devel. | 1985 |
| Mr. John Shearman | Exec. Director of Marketing & Cannabis Bus. | NA |
| Mr. Tony Benson | Managing Director of EMEA | NA |
| Ms. Janice Meraglia | VP, Gov. & Military Programs | NA |
| Ms. MeiLin Wan | VP of Textile Sales | NA |
| Dr. Stephen Hughes | Director of DNA Programs | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.